Validated hpv16-derived stimulation peptides

Abstract

The present invention relates to an in vitro method for producing an immunoreactive agent against human cancer cells infected with HPV16-related virus, said method comprising expressing an at least partial nucleic acid sequence encoding an immunoreactive agent obtained from an immune cell stimulated by a complex comprising a human leukocyte antigen (HLA) and a stimulation peptide (stimulation complex), wherein said stimulation peptide (i) consists of an amino acid sequence selected from SEQ ID NOs: 1 and 2 and said HLA is from HLA supertype HLA-A01; (ii) consists of an amino acid sequence of SEQ ID NO: 11 and said HLA is from HLA supertype HLA-A02, (iii) consists of an amino acid sequence selected from SEQ ID NOs:34 to 37 and said HLA is from HLA supertype HLA-A03/A11; (iv) consists of an amino acid sequence selected from SEQ ID NOs:60 and bland said HLA is from HLA supertype HLA-A24; (v) consists of an amino acid sequence selected from SEQ ID NOs:61, 76, and 77 and said HLA is from HLA supertype HLA-B07; or (vi) consists of an amino acid sequence selected from SEQ ID NOs:61 and 85 to 92 and said HLA is from HLA supertype HLA-B15; and wherein an HPV16-derived peptide consisting of the same amino acid sequence as said stimulation peptide has been verified to be presented by human HPV16-positive cancer cells, and to methods and uses related thereto.

Dependencies are inferred from the claim text.